Results 141 to 150 of about 2,510,319 (291)
Monotonicity and Nash implementation in matching markets with contracts [PDF]
We consider general two-sided matching markets, so-called matching with contracts markets as introduced by Hatfield and Milgrom (2005) and analyze (Maskin) monotonic and Nash implementable solutions.
Claus-Jochen Haake, Bettina Klaus
core
Translating whole‐genome doubling into precision medicine in cancer
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley +1 more source
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley +1 more source
Credible Group Stability in Multi-Partner Matching Problems [PDF]
It is known that in two-sided many-to-many matching markets, pair-wise stability is not logically related with the (weak) core, unlike in many-to-one matching markets (Blair, 1988).
Hideo Konishi, M. Utku Ünver
core
CEACAM1 participation in breast cancer progression
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Incomplete Information and Small Cores in Matching Markets [PDF]
We study Bayesian Nash equilibria of stable mechanisms in centralized matching markets under incomplete information. We show that truth-telling is a Bayesian Nash equilibrium of the revelation game induced by a common belief and a stable mechanism if and
Jordi Massó, Lars Ehlers
core
Spatial biology in cancer epigenetics
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley +1 more source
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche +10 more
wiley +1 more source
Transformation from arbitrary matchings to stable matchings
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
openaire +3 more sources

